Ventricular Tachycardia Ablation Clinical Trials.
Catheter ablation is an increasingly used treatment option for patients with ventricular tachycardia (VT) in the setting of structural heart disease. Although there are extensive data from several retrospective studies as well as prospective nonrandomized observational studies, there are limited data from relatively few randomized controlled trials, especially comparing VT ablation with antiarrhythmic drugs. In this review, the authors aim to summarize the major studies examining efficacy of VT ablation in patients with structural heart disease, discuss barriers to enrollment and completion of randomized clinical trials, and propose areas of future research in the field.
Electrophysiology Section, Division of Cardiology, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104, USA.
Jackson J
JJ
Liang
Electrophysiology Section, Division of Cardiology, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104, USA.
Daniele
D
Muser
Electrophysiology Section, Division of Cardiology, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104, USA. Electronic address: Pasquale.santangeli@uphs.upenn.edu.
Pasquale
P
Santangeli
D017115:Catheter Ablation; D002986:Clinical Trials as Topic; D006801:Humans; D017180:Tachycardia, Ventricular / Q000503:physiopathology / Q000601:surgery; D016896:Treatment Outcome
Catheter ablation; Clinical trial; Outcome; Ventricular tachycardia